Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL

6562 Background: Age >60 years has been identified as a poor prognostic factor in patients with follicular NHL (FL). Such patients are susceptible to treatment-related complications that may limit treatment options. We evaluated whether the efficacy and safety of the yttrium 90 (90Y) ibritumomab tiuxetan (IT) regimen were affected by patient age. Methods: Integrated analyses of 211 patients with B-cell NHL in 4 clinical trials compared 3 patient groups: group 1, <60 years; group 2, 60–69 years; and group 3, ≥70 years. Median ages were 49, 65, and 75 years, respectively. All patients had bone marrow involvement ≤25%, platelet counts ≥100,000/mm3, and ANC ≥1500/mm3. Results: Most patients had FL (78% in group 1, 62% in group 2, 73% in group 3) and tumors ≥5 cm (56% in group 1, 60% in group 2, 53% in group 3%). All patients had received prior therapy: 1–3 regimens, 74–85%; ≥4 regimens, 15–31%. The majority (94% in group 1, 81% in group 2, 85% in group 3%) had stage III/IV NHL at study entry. Baseline prognos...